Skip to main content
$0.024 (0%)

High

$0.03

Low

$0.02

Trades

24

Turnover

$54,432

Volume

2,170,184
30 June 2023 at 3:59pm
If you were already registered, log in here.

Short Interest

ASIC data, 2 Feb 2021

% Shorted

0.00% 0.00
vs 0.00% prior report

Most Shorted Rank

662nd
of 711 shorted ASX stocks

Peak Short

0.10%
Nov 2020

Days to Cover

0.0
at 50d avg vol
Subject
1AD Ann: Notification regarding unquoted securities - 1AD

1AD Ann: Results of Annual General Meeting

1AD Ann: AGM presentations & first iCAR-T data

1AD Ann: Cleansing Notice under Section 708A

1AD Ann: Application for quotation of securities - 1AD

1AD Ann: Second US patent for AD-214

1AD Ann: Change in Director Interest Notice x 2 (PM & RP)

1AD Ann: Notification of cessation of securities - 1AD

1AD Ann: Proposed issue of securities - 1AD

1AD Ann: Spark Plus engaged for SE Asia IR - shares in lieu of fees

1AD Ann: R&D Tax Incentive Refund received

1AD Ann: Notice of Annual General Meeting/Proxy Form

1AD Ann: Virtual Meeting Voting and Registration Guide

1AD Ann: Jobkeeper s323DB Notice

1AD Ann: Change of Director's Interest Notice

1AD Ann: Company Presentation - AusBiotech and Bio-Europe

1AD Ann: Quarterly Appendix 4C and Activities Report

1AD Ann: BTB funding transferred to AD-214 inhalation program

1AD Ann: Notification of Date of 2021 AGM

1AD Ann: New pre-clinical data presented at Boston conference

1AD Ann: Corporate overview and IRD Invest 2021 presentation

1AD Ann: $4.0M Non-Dilutive Financing with Victorian Government

1AD Ann: Appendix 4G and Corporate Governance Statement

1AD Ann: Annual Report to shareholders

1AD Ann: Preliminary Final Report

1AD Ann: Carina collaboration webinar presentation

1AD Ann: CAR-T collaboration with Carina Biotech

1AD Ann: Quarterly Appendix 4C and Activities Report

1AD Ann: Notification of cessation of securities - 1AD

1AD Ann: Webinar and presentation on AD-214 strategy

1AD Ann: AD-214 pathway to IPF efficacy studies

1AD Ann: Change in Director Interest Notice x 4

1AD Ann: Notification of cessation of securities - 1AD

1AD Ann: Operations Update & Cleansing Notice

1AD Ann: Application for quotation of securities - 1AD

1AD Ann: AdAlta secures AD-214 resupply

1AD Ann: R&D Tax Incentive Facility

1AD Ann: Notification of Expiry of Listed Options - Correction

1AD Ann: Notification of Expiry of Listed Options

1AD Ann: AdAlta corporate presentation, upcoming events

1AD Ann: GE Healthcare collaboration advances to next stage

1AD Ann: AdAlta granted Japanese patent for AD-214

1AD Ann: CSO presentation at ILD Drug Development Summit

1AD Ann: Quarterly Appendix 4C and Activities Report

1AD Ann: Mutiple Dose Part Of Ad-214 Phase I Trial Commenced

1AD Ann: Appendix 3G

1AD Ann: AdAlta Corporate Overview March 2021

1AD Ann: Investor briefing-AD-214 top line single dose safety results

1AD Ann: AdAlta to host investor briefing 10 March

1AD Ann: Appendix 4D and Interim Financial Report

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX
S88
MAV
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS
MBM